News, Resources, and Events Tagged "Jacob Sherkow"
The Unsettled Debate at the Heart of the Henrietta Lacks Case
“People think that because they have autonomy over their physical body, that means they have a, quote, property interest in it. That is just bluntly wrong,” Jacob Sherkow,…
Regulating Direct-to-Consumer Polygenic Risk Scores
Recently, polygenic risk scores (PGSs)—genome-wide measures of individuals’ genetic propensities—have come to consumers. PGSs are now directly available to individuals to assess type 2 diabetes risk,…
Supreme Court Sides with Sanofi, Regeneron in Patent Fight with Amgen
Gorsuch acknowledged a patent does not need to disclose each single possible embodiment of the invention. But he added that examples of the claimed class need to have some common…
Pharma Patents Threatened by Federal Circuit, Petitions Say
If the Juno and Amgen decisions are left in place by the Supreme Court, no attempt to define an antibody will be enough to satisfy the Federal Circuit, said …
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
Shares of gene-editing leader Intellia Therapeutics have dropped 35% since late February, when the U.S. Patent and Trademark Office decided it would not grant patents that Intellia relied on in…
So, just how much are those CRISPR patents actually worth?
There was a single question conspicuously absent in all the discussion over last week’s CRISPR patent ruling (a single number, really): How much are the patents actually worth?
How do we encourage innovation on “long COVID”?
Since the pandemic began, numerous recovered COVID-19 patients have reported having “long COVID”: COVID-19 symptoms persisting well beyond the underlying viral infection period. Whether such a condition is…
Crispr Patent Ruling Picks Winners in Dispute Over Gene-Editing Technology
In the latest twist in a long-running legal dispute over a popular gene-editing tool, U.S. patent authorities ruled that the Broad Institute deserves the credit for inventing a way…
CRISPR’s Nobel Prize winners defeated in key patent claim for genome editor
According to a ruling by an appeal board of the U.S. Patent and Trademark Office (USPTO), a different group, led by the Broad Institute of MIT and Harvard, made…
CRISPR Ruling Invalidates Some Biotech Company Patents
The Broad Institute was the first to invent CRISPR-Cas9 technology for use in animal cells, the U.S. Patent and Trademark Office said, siding against two Nobel laureates in a…
Complex CRISPR Patent Decision Benefits Broad Institute, Editas
According to Jacob Sherkow, professor of law at the Innovation Center for Law and Technology at New York Law School, this represents a possible loss of $100 million to $10 billion in…
UC Berkeley loses CRISPR gene editing patent case
It’s a major blow for UC, representing a potential loss of $100 million to $10 billion in U.S. licensing revenues, according to Jacob Sherkow, a professor at the University…
UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies
Ending the latest chapter in a years-long legal battle over who invented CRISPR, the U.S. Patent and Trademark Office ruled on Monday that the revolutionary genome editing technology belongs…
Broad prevails in crucial ruling over CRISPR licensing
Ending the latest chapter in a years-long legal battle over who invented CRISPR, the US Patent and Trademark Office ruled on Monday that the revolutionary genome editing technology belongs to…
The Antibody Paradox
Antibodies constitute a staggering $145 billion annual market—an amount projected to almost double by 2026. Consequently, patents covering antibodies are among the most valuable in the patent system. But antibody…
New CRISPR patent hearing continues high-stakes legal battle
On that question, “we have never received a satisfactory answer from the patent office,” says Jacob Sherkow, a patent attorney with the University of Illinois College of Law…
The Earth BioGenome Project 2020: Starting the clock
November 2020 marked 2 y since the launch of the Earth BioGenome Project (EBP), which aims to sequence all known eukaryotic species in a 10-y timeframe. Since then, significant progress has been…
Ethical, legal, and social issues in the Earth BioGenome Project
The Earth BioGenome Project (EBP) is an audacious endeavor to obtain whole-genome sequences of representatives from all eukaryotic species on Earth. In addition to the project’s technical and…
What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies?
The FDA has now authorized three vaccines and several treatments (including both monoclonal antibodies and small-molecule drugs) for the prevention and treatment of COVID-19. But the initial evidence supporting these…
Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds
Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents covered key ingredients — or innovative new molecules — in pricey biologic medicines, underscoring concerns…
Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents
A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what. …
Preprint servers and patent prior art
Posting papers on preprint servers creates patent 'prior art' and is likely to affect the patentability of any underlying invention.
The multibillion dollar claim for Henrietta Lacks’s cell line
Rosalind English talks with Professor Jacob Sherkow about a recent claim brought by the Henrietta Lacks Estate, against Thermo Fisher Scientific, in the USA. Lacks's "immortal cells" have benefited …
Moderna and U.S. at Odds Over Vaccine Patent Rights
Moderna’s patent application names several employees as the sole inventors of a crucial component of its coronavirus vaccine, excluding three government scientists.
Boston University Law Review Online Symposium: Rewriting Nature: The Future of Genome Editing and How to Bridge the Gap Between Law and Science
History will mark the twenty-first century as the dawn of the age of precise genetic manipulation. Breakthroughs in genome editing are poised to enable humankind to fundamentally transform life on…
University of Illinois law professor talks vaccine passport debate
Professor Jacob Sherkow from the University of Illinois College of Law talks vaccine passport debate.
How would the proposed American Pandemic Preparedness Plan help address underinvestment in pandemic-related innovation?
Complete author list: Jacob S. Sherkow (Former Edmond J. Safra/Petrie-Flom Centers Joint Fellow-in-Residence) Lisa Larrimore Ouellette, Nicholson Price (Former Academic Fellow), and Rachel Sachs (Former Academic Fellow) Historically, the…
In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Cassava Sciences CEO Remi Barbier on Monday shifted his defense of the company’s embattled treatment for Alzheimer’s disease: The drug is safe, he said, therefore the…
Governance Choices of Genome Editing Patents
There are a variety of governance mechanisms concerning the ownership and use of patents. These include government licenses, compulsory licenses, march-in rights for inventions created with federal funding, government use…
What’s happening with proposals for a WTO waiver of COVID-related IP?
If COVID-19 were a pandemic movie, we’d be very close to the end since we’ve identified several excellent vaccines; the conventional biomedical innovation narrative often ends…
Voices of biotech leaders
What will be the most important developments in biotech business and its contributions across the globe in the coming years? In which areas will life-science enterprises make the biggest impact…
Texas Doctor Spreads False Claims About COVID-19 Vaccines
Federal officials authorized two mRNA vaccines for COVID-19 after they were determined to be safe and effective against symptomatic illness in clinical trials. But a Texas doctor, in a widely…
Reining in drug patents isn’t a silver bullet against high drug prices
One of the top orders of business for the Biden administration is curbing drug prices. It’s a laudable goal. High drug prices are a major public health concern;…
Are patents the cause of—or solution to—COVID-19 vaccine innovation problems? (No!)
Full author list: Jacob Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow), Lisa Larrimore Ouellette, Nicholson Price (Former Academic Fellow), and Rachel Sachs (Former Academic Fellow) Are patents…
EpiPen, Patents, and Life and Death
Drug pricing disputes, while significant public health concerns, are not typically immediate life or death matters. But they may be for certain emergency medicines, medicines used for potentially lethal and…
Regulatory Sandboxes and the Public Health
Recently, administrative agencies around the world have engaged in a grand experiment to regulate new technologies: regulatory sandboxes. Regulatory sandboxes allow developers, in cooperation with an agency, to conduct limited…
A U.S. court ruling may force biologics makers to review patent protections
In a decision with broad implications for the pharmaceutical industry, a U.S. appeals court recently restricted wide-ranging patent claims for antibody treatments, a ruling legal experts say may force…
Why aren’t therapeutic antibodies being used more to treat COVID-19?
Complete author list: W. Nicholson Price II (Former Academic Fellow), Rachel Sachs (Former Academic Fellow), Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow), and Lisa Larrimore…
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
In the middle of a record number of COVID-19 infections and deaths—and continued evidence of racial disparities in the pandemic’s effects—December brought some good…
How can policymakers encourage COVID-19 vaccine trials for children?
Complete author list: Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow), Lisa Larrimore Ouellette, Nicholson Price (Former Academic Fellow), and Rachel Sachs (Former Academic Fellow) The…
What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?
Complete author list: Rachel Sachs (Former Academic Fellow), Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow), Lisa Larrimore Ouellette, and Nicholson Price (Former Academic Fellow) When…
What role is AI playing in the COVID-19 pandemic?
Complete author list: Nicholson Price (Former Academic Fellow), Rachel Sachs (Former Academic Fellow), Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow), and Lisa Larrimore Ouellette Promising…
NIH fails to disclose enough details about drug licensing, watchdog report finds
Amid increasing debate over the cost of prescription drugs, a federal watchdog agency found the National Institutes of Health does not consider whether a medicine it discovered and licensed to…
FDA gene therapy holdups suggest closer scrutiny by agency
The Food and Drug Administration cleared the first two gene therapies for inherited diseases in short order, with just a year and a half separating historic approvals for the blindness…
Rogues and enforcers: Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing
The HHGE report relies, in substantial part, on using law as an instrument of international governance of heritable genome editing. Although this is understandable, actually enforcing such a system&mdash…
Congress Needs To Decide If Gene Editing Is Permissible For Sperm And Eggs
In a recent article in The Journal of Law, Medicine, and Ethics, Professor I. Glenn Cohen of Harvard Law School, Professor Jacob Sherkow of the University of Illinois Urbana-Champaign, and…
Congress must clarify limits of gene-editing technologies
Genome editing of human embryos represents one of the most contentious potential scientific applications today. But what if geneticists could sidestep the controversy by editing sperm and eggs instead? According…
The two months in 1980 that shaped the future of biotech
Tuesday, December 2, marked the fourth, quietest, but not the least important of this string of biotech events. The U.S. Patent and Trademark Office granted U.S. Patent No. 4,237,224, &ldquo…
Homemade COVID-19 Vaccine: Does it Work and is it Safe?
An effective COVID-19 vaccine is a concern of most people all over the world, and now, some wonder if having it homemade is the way to go. In fact, 'How…
Gene Editing Sperm and Eggs (not Embryos): Does it Make a Legal or Ethical Difference?
Heritable, human genome editing constitutes one of the most contentious issues facing science policy. This was starkly illustrated by Dr. He’s unsafe, unethical, and irresponsible editing of twin…
The Chronicles of CRISPR
Over the past 25 years, GEN’s editor-at-large Kevin Davies, PhD, has written a series of books tackling different aspects of the genetics and genomics revolution. His most successful was…
Don’t Mess Around with Homemade COVID-19 Vaccines, Scientists Plead
Yes, the idea of people inoculating themselves sounds absurd. And thankfully, there’s no reason to automatically think people trying these recipes are very widespread. But part of the…
Do-it-yourself COVID-19 vaccines fraught with public health problems
CHAMPAIGN, Ill. — Well-intentioned “citizen scientists” developing homemade COVID-19 vaccines may believe they’re inoculating themselves against the ongoing pandemic, but the practice of self-experimentation with do-it-yourself…
Some scientists taking ‘DIY inoculations’ instead of waiting for COVID-19 vaccine
TORONTO -- Nearly 200 COVID-19 vaccines are in development, and more than 60 of those are at various stages of human testing. But for some, a vaccine isn’t coming soon…
Bioethicists condemn DIY COVID-19 vaccine efforts
Across the country, a small handful of scientists are brewing up their own homemade and unproven COVID-19 vaccines and giving them to friends, family and themselves. These scientists hail from…
Patent board delivers blow to University of California over its CRISPR invention claims
Making a key ruling in a long-running battle over lucrative patent rights, a government patent board has knocked down the University of California’s initial claims that its scientists…
Self-experimentation, ethics, and regulation of vaccines
Complete author list: Christi J. Guerrini, Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow in Ethics of Technology and Biomedical Innovation), Michelle N. Meyer (Former Academic…
The latest round in the CRISPR patent battle has an apparent victor, but the fight continues
The long-running patent battle over CRISPR, the genome editor that may bring a Nobel Prize and many millions of dollars to whoever is credited with its invention, has taken a…
Are COVID-19 vaccine advance purchases a form of vaccine nationalism, an effective spur to innovation, or something in between?
No vaccine for the novel coronavirus has been approved anywhere. Nevertheless, governments and international organizations around the world are announcing deals for billions of dollars to procure tens of millions…
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
Complete author list: Lisa Larrimore Ouellette, Nicholson Price (Former Academic Fellow), Rachel Sachs (Former Academic Fellow), and Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow in…
Multi-Agency Funding for COVID-19 Vaccine Development
Complete author list: Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow in Ethics of Technology and Biomedical Innovation), Lisa Larrimore Ouellette, Nicholson Price (Former Academic Fellow),…
How is the NIH seeking to encourage investment in diagnostic testing for COVID-19?
Complete author list: Rachel Sachs (Former Academic Fellow), Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow in Ethics of Technology and Biomedical Innovation), Lisa Larrimore Ouellette,…
Are COVID-19 vaccine advance purchases a form of vaccine nationalism, an effective spur to innovation, or something in between?
Complete Author List: Nicholson Price (Former Academic Fellow), Rachel Sachs (Former Academic Fellow), Jacob S. Sherkow (Former Edmond J. Safra Center and Petrie-Flom Center Fellow in Ethics of Technology and…
Health Law Workshop: Jacob S. Sherkow: Adaptive Intellectual Property
Presentation This presentation is not available for download. About the Presenter Jacob S. Sherkow is the 2019-2020 Edmond J. Safra Center and Petrie-Flom Center Fellow in Ethics of Technological and…
The Complexity of the CRISPR Patent Licensing Landscape for Agriculture
Prof. Jacob Sherkow presented his talk, "The Complexity of the CRISPR Patent Licensing Landscape for Agriculture," in Keystone, Colorado, for a conference jointly hosted by Colorado State University and OECD.…
Controlling CRISPR Through Law: Legal Regimes as Precautionary Principles
From the abstract: Since its advent in 2012, CRISPR has spawned a cottage industry of bioethics literature. One principal criticism of the technology is its virtually instant widespread adoption prior to…
10x Genomics Showing ‘Little Concern’ for Patent Lawsuit Consequences, Customers Say
From the article: The permanent injunction is set to take effect Wednesday, Aug. 28. The appeals court is likely to make a ruling on whether it will stay the injunction today…
Patent Eligibility Reform and Public Health
From the article: The 2013 Decision by the Supreme Court of the United States in Association for Molecular Pathology v. Myriad Genetics, Inc. was seen by many as a triumph for…
Welcoming Fellow-In-Residence Jacob Sherkow
Along with our partners at the Edmond J. Safra Center for Ethics at Harvard University, the Petrie-Flom Center is thrilled to announce our new jointly hosted Fellow-in-Residence, Jacob Sherkow. Jacob…
Genome Editing: Rights and Wrongs: A Health Policy and Bioethics Consortium
Gene-editing technologies offer substantial promise in treating disease, but their use raises important ethical and public health questions about how these innovations should be applied and regulated. Different groups have…